Codeine Works for Some People and Poisons Others. Your Genes Determine Which.

CYP2D6 is a critical liver enzyme. Its job is to break down medications into forms your body can use or eliminate. Codeine is chemically inactive until CYP2D6 converts it to morphine. Tramadol, hydrocodone, and dozens of psychiatric medications depend on this same enzyme.

The CYP2D6 gene varies widely. Some people inherit two working copies; others inherit one broken copy, two broken copies, or even extra copies. Poor metabolizers, carrying two non-functional variants, comprise roughly 7 to 10 percent of people of European ancestry. Ultra-rapid metabolizers, with gene duplications, represent about 1 to 3 percent. A poor metabolizer taking a standard dose of codeine has morphine accumulating in their bloodstream with no way to clear it, creating overdose risk from a normal prescription. An ultra-rapid metabolizer needs three times the standard dose just to feel any effect.

If you’ve been prescribed codeine and experienced severe drowsiness, confusion, or breathing difficulty at low doses, you’re likely a poor metabolizer. If your doctor prescribed codeine and you felt no pain relief despite higher doses, you might be ultra-rapid. Either way, your standard dose is wrong.

CYP2C19 activates several important medications. Clopidogrel, a blood thinner prescribed after heart attacks and stent placements, is a prodrug. Your body must convert it to its active form using CYP2C19. If this enzyme is slow or absent, clopidogrel never becomes active. Your blood never thins. Your stent clots.

Poor metabolizers of CYP2C19 comprise roughly 2 to 15 percent of the population, depending on ancestry. East Asian ancestry shows higher rates of poor metabolism. A poor metabolizer taking clopidogrel receives zero antiplatelet benefit from the drug, despite being at maximum cardiovascular risk. Meanwhile, ultra-rapid metabolizers convert clopidogrel so quickly that standard doses produce excessive bleeding.

You might not notice this failure in the moment. Your cardiologist prescribed clopidogrel. You took it. Your bloodwork showed normal function. Then, months later, your stent re-thrombosed. You had a second heart attack. Your doctor never checked whether you could actually activate the medication.

Warfarin is one of the oldest blood thinners. It works, but the therapeutic window is narrow. Too little and your blood clots. Too much and you bleed internally. Dose adjustment is constant, guided by INR blood tests. CYP2C9 controls how fast your liver breaks down warfarin. Variants in this gene dramatically alter how much warfarin your body can tolerate.

Poor metabolizers of CYP2C9 represent roughly 5 to 10 percent of people of European ancestry. A poor metabolizer starting a standard warfarin dose can rapidly develop INR levels that are dangerously high, causing spontaneous bleeding in the gut, brain, or other organs. These people need 30 to 50 percent less warfarin than the average patient. Without genetic testing, their dose is guessed wrong from day one.

You might experience unexplained bruising, blood in your urine, or nosebleeds that won’t stop. Your doctor increases your INR testing frequency, but the standard starting dose was already too high for your genes.

Warfarin works by blocking VKORC1, an enzyme that recycles vitamin K. By blocking recycling, warfarin prevents your blood from clotting. VKORC1 itself is the drug’s target, not just a metabolizer. Genetic variants in VKORC1 change how sensitive this enzyme is to warfarin. Some people’s VKORC1 is highly sensitive; others are resistant.

The VKORC1 -1639G>A variant is common, carried by roughly 40 percent of people of European ancestry. People with the A allele have reduced vitamin K recycling efficiency, making them extremely sensitive to warfarin. A patient with the sensitive VKORC1 variant plus a CYP2C9 poor-metabolizer variant faces compounded risk: slower drug clearance plus higher drug sensitivity equals severe bleeding risk even at low doses.

You might bleed excessively from minor injuries, develop spontaneous bruising, or experience internal bleeding months after starting warfarin. Blood tests show your INR is in the therapeutic range, but your genes made you sensitive to warfarin at that level.

Statins lower cholesterol by inhibiting HMG-CoA reductase. They work in your liver. SLCO1B1 is the transporter that moves statins into liver cells. Without proper transport, statins remain in your bloodstream at high concentrations instead of concentrating where they work. They begin damaging muscle cells instead.

The SLCO1B1 rs4149056 C allele is carried by roughly 15 percent of the population. People with this variant have reduced statin uptake into liver cells, meaning simvastatin and pravastatin accumulate in muscle tissue, causing statin-induced myopathy at standard doses. This manifests as muscle pain, weakness, and elevated creatine kinase (CK), often months after starting the medication.

You start a statin for cholesterol. Weeks later, your legs ache. Your doctor attributes it to exercise. You stop exercising. The pain worsens. A month later, your CK is elevated. Your doctor stops the statin and calls it a drug side effect. You never know that your SLCO1B1 variant made you intolerant to standard doses.

Thiopurines like azathioprine and 6-mercaptopurine are powerful immunosuppressive drugs used in autoimmune disease and cancer. They work by poisoning rapidly dividing cells. Your bone marrow, which produces blood cells constantly, is vulnerable. TPMT controls how quickly your body breaks down thiopurines. Poor metabolizers cannot clear them efficiently.

TPMT poor metabolizers comprise roughly 0.3 percent of the population, but among those with East or South Asian ancestry, rates are higher. A poor metabolizer receiving standard thiopurine doses accumulates toxic metabolites that destroy bone marrow function, causing severe anemia, dangerous infections from low white blood cell counts, or life-threatening low platelet counts. These effects can be catastrophic and irreversible.

You’re prescribed azathioprine for lupus. Weeks later, you develop severe infections, unexplained anemia, and bruising. Your bone marrow has been destroyed. You required hospitalization. Your doctor stopped the drug, but the damage was already done.